Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...
The conditions included stroke, sepsis, heart failure, pneumonia — infectious, kidney failure — acute, and stomach and ...
An experimental gene therapy might one day give people with heart failure a new lease on life. The therapy prompted the pigs’ ...
The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.
Mark H. Drazner, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues present an expert consensus decision pathway for diagnosing and managing acute myocarditis in ...
High-flow nasal oxygen (HFNO) is noninferior to noninvasive ventilation (NIV) for endotracheal intubation or death within ...
A University of Nottingham study revealed that prolonged paracetamol use in individuals 65 and older increases the risk of ...
Are you one of those 38 million people wondering whether you can reverse kidney illnesses? CKD, or chronic kidney disease, cannot be cured, although you can control it. Acute kidney damage, also ...
In a 2024 guidance document issued by the American College of Cardiology and published online in the Journal of the American ...
Chronic heart failure (CHF) is associated with frequent hospitalizations and high mortality. It affects more than 5 million individuals in the USA, and another 660,000 new cases are diagnosed each ...
Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the ...
In infants with cardiomyopathy-associated chronic HF, baseline LVEF of less than 40% and β blocker use indicate a decreased chance of LVEF normalization.